Eosinophilic esophagitis (EoE) is a chronic disease characterized by eosinophil-rich esophageal inflammation. 1 The prevalence, estimated at 0.05% to 0.1% in the United States, appears to be increasing, and male subjects of all ages are disproportionately affected. 2 Patients with EoE, particularly children, can present with a spectrum of symptoms. [3] [4] [5] [6] The histologic and clinical responses to elemental and elimination diets provide strong evidence that food antigens are important contributors to EoE. [7] [8] [9] Cow's milk (CM) has consistently been shown to be a dominant factor, with wheat, egg, soy, and peanut also often causally related. 10, 11 However, the nature of the immune response to food and the role of this immune response in disease pathogenesis remains incompletely understood.
There are multiple lines of evidence arguing against a pathogenic role for food-specific IgE (sIgE) antibodies in patients with EoE, including (1) the lack of immediate symptoms on food ingestion, (2) the poor response to anti-IgE therapy observed in clinical trials, and (3) the low predictive value of skin prick tests or the Immuno Solid-Phase Allergen Chip (ISAC) microarray for identifying causative foods. [3] [4] [5] [6] [11] [12] [13] [14] [15] However, a role for IgE cannot be entirely excluded. Our group has demonstrated that food sIgE is common in patients with EoE 12 and that sIgE assays that use high-capacity ImmunoCAPs demonstrate positive results to CM proteins (a-lactalbumin [ 16 Moreover, we have reported that low-titer sIgE to CM (0.10-1.0 IU/mL) is associated with histologic remission in pediatric patients with EoE on a CM elimination diet. 15 Another antibody isotype that has drawn attention in patients with EoE is IgG 4 . Although IgG 4 has structural features that promote anti-inflammatory activity and is often considered a mediator of allergen tolerance, 17, 18 2 groups have recently reported the presence of specific IgG 4 (sIgG 4 ) antibodies to food extracts, including CM and wheat, in sera and esophageal tissue biopsy specimens of adults with EoE. 13, 19 The clinical significance of those results is not clear, in part because the prevalence of sIgG 4 to food proteins in the general population is not well established and because there has not been a parallel analysis with sIgE. Moreover, the sIgG 4 response to foods has not been reported in children with EoE, nor have results been stratified to assess for a difference between male and female subjects.
To address these shortcomings, we investigated serum IgE and IgG 4 responses to CM, wheat, egg, soy, and peanut by using molecular allergen-based assays in pediatric patients with EoE. We compared the results with those of similarly aged children from a Boston-based birth cohort (Project Viva) unselected for any atopic risk or disease, resulting in a natural population including allergic and nonallergic children. 20 We also extended the analysis to explore the effects of sex, age, and milk consumption on sIgG 4 levels.
METHODS Subjects
Sera were collected after achieving informed consent at Nationwide Children's Hospital (Columbus, Ohio [n 5 35] ) or the University of Virginia (Charlottesville, Va [n 5 36] ) from 71 children with newly established or active EoE in whom diagnosis had been confirmed by esophageal biopsies demonstrating 15 or more eosinophils per high-power field (eos/hpf). The control subjects included 210 children randomly selected from a Boston-based birth cohort (Project Viva) study, which included blood collection from 647 children in the early teenage years. Inclusion criteria and enrollment details for the control subjects and groups for secondary analysis are located in the Methods section in this article's Online Repository at www.jacionline.org.
Immunoassays
Using the ImmunoCAP 250 instrument (Thermo Fisher Scientific, Uppsala, Sweden), sera were assayed for sIgE to CM, wheat, egg white, soy, and peanut extracts; total IgE; sIgG 4 , rAra h 1, rAra h 2, rAra h 3, rAra h 8, and rAra h 9; and total IgG 4 (see Table E1 in this article's Online Repository). Only sera that were positive for sIgE to whole CM extract were assayed for sIgE to individual CM proteins. Assays for lactoferrin and a-gal were accomplished by coupling biotinylated lactoferrin purified from CM (Sigma-Aldrich, St Louis, Mo) or a-gal linked to human serum albumin (V-Labs, Covington, La) to a streptavidin ImmunoCAP.
IgG 4 results were expressed in micrograms per milliliter (positive 5 > _0.07 mg/mL). IgE results were expressed in international units per milliliter (positive 5 > _0.10 IU/mL). For quantitative comparison of sIgE and sIgG 4 results, 1 IU/mL IgE was converted to 2.42 ng/mL. 22 Details on total IgG 4 measurements and other specific IgG antibody assays are provided in the Methods section in this article's Online Repository.
Statistics
Demographic/clinical data and antibody titers were compared between patients with EoE and control subject by using the Mann-Whitney, Student t, or x 2 tests (or the Fisher exact test, where appropriate). Differences in antibody titers were assessed across multiple groups by using the Kruskal-Wallis test. Changes in antibody titers before and after elimination diets were evaluated with the Wilcoxon signed-rank test. Associations between CM sIgE and sIgG 4 levels and EoE status were assessed by using logistic regression analyses. Models were adjusted for age, sex, and milk consumption. Milk consumption was assessed by means of questionnaire or clinical history and dichotomized as yes or no. Statistics were performed and visualized with STATA SE/11 software (StataCorp, College Station, Tex) and GraphPad Prism software (version 7; GraphPad Software, La Jolla, Calif).
RESULTS

Subjects' demographics and clinical history
Children with EoE and control children were similar with respect to age, body mass index, and asthma history, although the EoE group included children with a wider range of ages (Table I) . In keeping with the male dominance of this disease, boys were a larger percentage of the EoE cohort. Both groups were predominately white; however, the proportion of nonwhite subjects was significantly greater among the control subjects compared with patients with EoE. Total IgE levels and reported histories of rhinitis, eczema, and food allergy were greater among children with EoE than control children.
All of the patients with EoE studied here had active EoE; that is, an esophageal biopsy specimen had shown 15 or more eosinophils/hpf from 1 or more esophageal biopsy specimens at the time of enrollment, with a median peak eosinophil count of 40 eosinophils/hpf (interquartile range [IQR], 25-60 eosinophils/ hpf). All but 6 patients with EoE had been treated with a proton pump inhibitor. 23 The most commonly reported gastrointestinal symptom among the patients with EoE was dysphagia, followed by abdominal pain, vomiting, reflux, and food impaction. A family history of EoE or reflux was common (20%) among patients with EoE. Approximately three quarters of the patients with EoE (n 5 53/ 71) reported CM consumption compared with 98% in the control population. Of the 18 patients with EoE avoiding CM, 2 were exclusively avoiding CM, whereas 16 were avoiding CM and at least 1 other food. The questionnaire used to assess clinical history for the control children did not include questions relating to gastrointestinal symptoms, and esophagoscopy was not performed on the control subjects.
Screening for sIgG 4 
to molecular food allergens in patients with EoE
To begin to define the nature of the IgG 4 response to food allergens in patients with EoE, we investigated sera from a subset of Table E1 ). The highest titers of sIgG 4 were seen to Bos d 4, Bos d 5, Bos d 8, and gluten, although sIgG 4 to other food proteins were also common (Fig 1) . Bos d 4 and Bos d 5 are purified proteins, whereas both Bos d 8 and gluten represent mixtures of closely related proteins. Because of the pronounced magnitude of the sIgG 4 to CM proteins and the fact that CM is often reported to be the most common causal food in patients with EoE, 7, 8 subsequent assays focused on the response to CM. The specificity of the IgG 4 assays for Bos d 4, Bos d 5, and Bos d 8 was supported by the results of absorption studies using purified proteins conjugated to Sepharose beads (see Fig E1, A, in this article's Online Repository). Quantitative accuracy was validated by means of comparison to RIAs using 3 different anti-IgG 4 mAbs (see Fig  E1, B) . Further studies using Sepharose conjugated to protein G or mAbs (to bind serum IgG or IgG 4 , respectively) demonstrated that the IgG response to CM proteins in patients with EoE is predominantly IgG 4 (see Fig E2 and Table E2 in this article's Online Repository).
Characterizing sIgG 4 to CM proteins in children with EoE and control children
We next extended the investigation of CM proteins to include all 71 patients with EoE and the 210 control subjects. Although antibodies to at least 1 CM protein were detectable in almost all of the subjects in both groups (> _97%), levels of sIgG 4 to Bos d 4, Bos d 5, and Bos d 8 were significantly greater in patients with EoE than in control subjects (each P < .001; Table II) .
We also compared sIgG 4 levels to CM proteins in the 2 groups as a function of whether subjects produced sIgE to CM (Table I) . sIgG 4 levels to Bos d 4, Bos d 5, and Bos d 8 were significantly greater in CM-sensitized children with EoE than in control children, regardless of whether the control children were sensitized (Fig 2) . For children with EoE who were not sensitized to CM, this response only achieved significance when compared with Bos d 5 and Bos d 8 in nonsensitized control subjects. As an additional control, sIgE and sIgG 4 levels to CM proteins were compared with those in a cohort of children (n 5 10) with a history of IgE-mediated anaphylaxis to CM (and who were not consuming dairy). The magnitude of the sIgG 4 responses were much greater in children with EoE than children with CMinduced anaphylaxis (see Table E3 in this article's Online Repository).
Because sIgG 4 titers to CM proteins in patients with EoE are very high, a direct comparison of the quantities of sIgG 4 with total IgG 4 was possible. There was a nonsignificant trend toward higher total IgG 4 levels among patients with EoE compared with control subjects (see Fig E3, A, in this article's Online Repository). Direct measurement of sIgG 4 to CM is limited by technical issues relating to background binding; however, a surrogate measurement for sIgG 4 to CM was obtained by summing the titers of sIgG 4 to Bos d 4, Bos d 5, and Bos d 8. 24 Expressing sIgG 4 to these 3 CM proteins as a percentage of total IgG 4 demonstrated that these antibodies represent a higher proportion of serum IgG 4 in patients with EoE compared with control subjects (P < .001; see Fig E3, B) .
Characterization of CM sIgE titers, IgG 4 /IgE ratios, and associations with EoE
Recently, our group has reported that IgE antibodies to food, specifically low-to moderate-titer sIgE to CM, is associated with milk wheat peanut egg soy 2 1 5 1 4 1 9 16 5 0 19 13 5 28 11 26 6 8 5 EoE among children scheduled for esophagoscopy. 12, 16, [25] [26] [27] Here we found that food sIgE levels were detected commonly in sera from the EoE cohort (76%), but interestingly, 36% of control children also had detectable sIgE to milk (Table I) . Although mostly of low titer (0.10-2.0 IU/mL), values were greater in children with EoE than control children. We additionally performed sIgE assays for the milk-specific components Bos d 4, Bos d 5, and Bos d 8 in sera from the 71 patients with EoE and 210 control subjects. Consistent with the results using CM extract, the frequency of detectable sIgE and levels of sIgE to all 3 milk components were greater in children with EoE than control children (Table III) .
Using the generally accepted value of 1 IU 5 2.42 ng of IgE, we converted units of sIgE to micrograms per milliliter 22 and calculated sIgG 4 /sIgE ratios for Bos d 4, Bos d 5, and Bos d 8 in subjects with detectable levels of both sIgG 4 and sIgE. Not unexpectedly, the prevalence of coexisting sIgG 4 and sIgE responses to Bos d 4, Bos d 5, and Bos d 8 was significantly greater among patients with EoE (each P < .001; Table IV) . Absolute values for sIgG 4 to CM proteins were commonly 10,000-fold greater than the IgE response to the same protein in sera from both children with EoE and control children.
Next, we determined the strength of the association for sIgG 4 to CM proteins with EoE. There were positive odds ratios (ORs) for all 3 CM proteins with moderate-to high-titer (> _1.0 mg/mL) and high-titer (> _10 mg/mL) sIgG 4 ( Table V) . The strongest association was for high-titer sIgG 4 to Bos d 8 (OR, 8.4; 95%,CI 4.3-15), but notably, these values were not significantly different than the ORs based on the presence of sIgE to CM proteins.
CM sIgG 4 levels adjusted for age, sex, and dairy consumption
Compared with control children, the EoE cohort had greater heterogeneity in age and diet and a higher percentage of boys (Table I ). Thus we assessed sIgG 4 responses to CM in subgroups of the EoE and control populations. In addition, we carried out regression analysis accounting for differences in age, sex, and CM consumption. First, we focused on children with EoE 10 to 18 years of age (median, 14.0 years) because these were more closely matched with children from the Project Viva cohort (median, 12.9 years; Fig 3) . Of the 29 boys and 15 girls in this EoE subgroup, most were consuming dairy products (86% and 80%, respectively). There was no clear difference in levels of sIgG 4 to CM proteins in those that consumed or avoided dairy, although this analysis was limited by the small number of children avoiding dairy in this age group. Titers of sIgG 4 to Bos d 4, Bos d 5, and Bos d 8 were greater in boys with EoE than control boys and also in girls with EoE than control girls (Fig 3) . Interestingly, there was a trend toward higher sIgG 4 levels to CM proteins in boys with EoE compared with girls with EoE, but the difference was only significant for Bos d 5 (P 5 .009). Conversely, in the control population there was a trend in the opposite direction between boys and girls. In keeping with this, logistic regression accounting for age and dairy consumption suggested a stronger association between high-titer sIgG 4 and EoE among boys than girls. For example, the adjusted ORs were greater than 20 for all 3 CM proteins in boys (Table VI) . In contrast, the ORs for girls were less than 10 to all 3 CM proteins, and in the case of Bos d 5, the OR was not statistically significant. However, in the combined model sex did not achieve significance as an interaction term. The group of younger children with EoE (2-9 years old) consisted of 20 boys and 7 girls. Of these, 37% were avoiding all dairy, and sIgG 4 Although the control population in the current study is not age matched to young children, this is a greater prevalence than a recent report that investigated sIgG 4 responses in a birth cohort at 2 years of age. 28 Total IgG 4 levels were not influenced significantly by sex, age, or CM consumption.
Because our initial experiments revealed that gluten sIgG 4 levels are often high in children with EoE, we also evaluated the strength of this association (see Fig E5 in dairy consumption) was lower for gluten (OR, 7.4; 95% CI, 3.0-18) than for CM proteins, and the association was not significant in girls (OR, 2.7; 95% CI, 0.8-9). We also sought to assess whether the association of sIgE responses to CM proteins was modified when the cohort was stratified by sex and adjusted for age and dairy consumption. Interestingly, and in contrast to the results for sIgG 4 , the association of sIgE responses to CM proteins (as well as extract) and EoE was not strengthened when accounting for age and dairy consumption, and evidence for a sex effect was minimal (see Fig E6 and Table E4 in this article's Online Repository).
Changes in sIgG 4 levels to CM proteins during a CM elimination diet
Finally, we monitored sIgG 4 levels to CM proteins to evaluate changes in titers when CM was removed from the diets of 13 children with EoE. 15 sIgG 4 levels to Bos d 4, Bos d 5, and Bos d 8 decreased by an average of approximately 40% to 60% after 6 to 8 weeks of the CM-free diet (Fig 4 and see Fig E7 in this article's Online Repository). Levels decreased in all subjects, including both those who experienced remission during the diet (n 5 8) and those who did not experience remission (n 5 5). Despite the decrease associated with the avoidance diet, mean levels were still greater in children with EoE than in control children.
DISCUSSION
Although sIgE levels to proteins from CM and other foods are common in patients with EoE, the titers are generally low, and the existing evidence does not support a causal role for IgE. 12, 16, 26, 27 The data presented here demonstrate that high titers of sIgG 4 to CM proteins are much more common in children with EoE than in early adolescent children from a birth cohort. To our knowledge, sIgG 4 levels to food allergens in patients with EoE are some of the highest, if not the highest, levels of sIgG 4 to any antigen reported in children. High IgG 4 levels relative to IgE is a serologic pattern often observed with allergen tolerance, including the response to allergen immunotherapy, receiving multiple bee stings, or living with a cat. [29] [30] [31] [32] [33] Thus EoE challenges the traditional view of IgG 4 because the high titers of sIgG 4 are clearly not associated with esophageal tolerance to CM.
In nonallergic subjects IgG 4 contributes a small proportion of serum IgG; however, the normal range for serum IgG 4 levels (0.01-2.00 mg/mL) implies greater variability than that seen with other IgG isotypes. 34 Using assays with different mAbs to specific heavy chain epitopes on IgG 4 , we provided confirmation of sIgG 4 and total IgG 4 quantitation. 35 Additionally, we found that sIgG 4 to CM proteins can represent a significant proportion of total IgG 4 , and it was clear that the sIgG 4 /sIgE ratios for Bos d 4, Bos d 5, and Bos d 8 were often 10,000:1 or greater. In contrast, food allergies with anaphylaxis are associated with high-titer sIgE levels, often in the presence of low levels of sIgG 4 . [36] [37] [38] Biologically, IgG 4 has several features in keeping with its role in allergen tolerance, including functional monovalency caused by the Fab arm exchange, inability to activate complement, and low affinity for most Fcg receptors. 17, [39] [40] [41] Thus the initial report demonstrating high levels of food sIgG 4 in the serum and esophagus of adults with EoE was intriguing. 13 Although subsequent investigations have confirmed those observations, 19 ,42 the assays for sIgG 4 used whole food extracts rather than purified proteins, were only semiquantitative, and were not compared with sIgE levels to the same foods.
Choosing control groups for studies on allergic disease is challenging because allergic sensitization is common in the community. Therefore, choosing only ''nonallergic'' or ''nonsensitized'' control subjects might exclude much of the population. Selecting control subjects who underwent esophagoscopy and did not meet the criteria for EoE also has pitfalls. 13, 19, 42 The control group used here was 210 early adolescent children from a cohort that was enrolled from before birth, and allergic history played no role in the recruitment. 20 The case-control data made it possible to assess the risk of EoE diagnosis associated with given titers of food sIgG 4 and sIgE. For example, high-titer (> _10 mg/mL) sIgG 4 to Bos d 8 had an OR of 8.4 (95% CI, 4.3-15) for EoE status. Intriguingly, when adjusted for age and CM consumption, there was a trend for a stronger association between IgG 4 levels and EoE for boys than girls. This latter finding is particularly interesting in light of the fact that EoE is more common in male subjects of all ages. 2 The significant ORs between IgG 4 responses to CM and EoE suggest that sIgG 4 could be associated with the inflammation and fibrosis seen in patients with EoE. This is not to say that the IgG 4 itself is causal but rather that it is almost certainly a component of the immune response that drives EoE. A real possibility is that CM sIgG 4 is an epiphenomenon in patients with EoE, perhaps related to an aberrant T H 2 or regulatory T-cell response. 43, 44 Accordingly, the fact that sIgG 4 is not sufficient to cause EoE is supported by the fact that 10% of control subjects also had high-titer sIgG 4 to CM proteins. This number is far greater than the number of cases of EoE that would be expected in an unselected population based on the national prevalence of the disease. 2 However, a pathogenic role for IgG 4 cannot be dismissed entirely. For example, EoE has features in common with IgG 4 -related disease. 13, 42, 45, 46 Not only are both diseases male dominant and steroid responsive, but biomarkers of IgG 4 -related disease, including IgG 4 -producing plasma cells and granular IgG 4 deposition, are present in the esophagus in patients with EoE. 13, 42 One possible scenario by which IgG 4 could be pathogenic would involve formation of extracellular immune complexes, which would be favored in a situation in which sIgG 4 antibody levels were largely restricted to a single allergen (group) and high concentrations of allergen were present in the tissue before Fab arm exchange occurred. This is consistent with our observation that sIgG 4 levels to CM proteins contributed more than 10% of total IgG 4 in 35% of our patients with EoE. Taken together, the question of whether high-titer sIgG 4 is an epiphenomenon or is mechanistically involved in the inflammation seen in patients with EoE is an important area for future inquiry.
Regardless of the exact role of IgG 4 in patients with EoE, the high titers of this antibody subclass might provide insight into reasons for failed tolerance. B-cell class-switch recombination (CSR) to IgG 4 shares elements that are involved in CSR to IgE, such as IL-4 and IL-13. However, IgG 4 has also been associated with high levels of IL-10 secreted from regulatory B and T cells. 32, 47, 48 Patients with EoE have increased levels of TGF-b1 localized to eosinophils and mast cells in the esophagus. 49, 50 TGF-b1 can suppress IgE CSR and also promote mast cell accumulation and eosinophil survival. T cells play a central role in CSR; thus upstream defects in T-cell activation or development could contribute to both the pathology and IgG 4 production in patients with EoE.
High serum levels of sIgG 4 to CM proteins in patients with EoE highlight a few practical issues related to in vitro diagnostics. One is the question of whether sIgG 4 levels to CM could be useful as a biomarker for the diagnosis or monitoring of EoE. Although clearly this would require prospective investigation, the difference in ORs between girls and boys reported here suggests that this question should be addressed with consideration to sex. Additionally, the findings here might shed light on why multiple studies using ISAC have provided results that conflict with results from ImmunoCAP in regard to the relationship between sIgE levels to food and EoE. For example, 2 groups recently showed little evidence for sIgE to CM proteins by using ISAC to study the sera of adults with EoE.
14,26 Previously, we reported this phenomenon in adult and pediatric patients with EoE but found that many of those sera produced positive results with ImmunoCAP. 16 Compared with ISAC, ImmunoCAP accommodates approximately 10 6 -fold more allergen. 51 Suppression of ISAC signals has been reported in adults with grass allergy receiving grass pollen subcutaneous immunotherapy. 29 The very high sIgG 4 /sIgE ratios for CM proteins seen here provide a simple explanation for the negative results using sIgE microarrays in patients with EoE. 14, 15, 26, 52 A limitation to our study is that many allergens of other foods have not been characterized and therefore are not available for use in commercial assays. Moreover, our data show IgG 4 responses to proteins from other foods that are included in the 6-food elimination diet. This is particularly true for wheat. We found high levels of sIgG 4 to gluten but not to Tri a 19 or other gliadins. Wheat is a complex source material containing potentially many candidate EoE-relevant allergens. In addition, wheat allergens can be cross-reactive with grasses and other foods. [53] [54] [55] Although we recognize the presence of high levels of sIgG 4 to gluten in patients with EoE, these results are currently difficult to interpret on a molecular level, as we were able to do for CM. Moreover, the association of sIgG 4 levels to gluten was not as strong as the association with sIgG 4 levels to CM proteins.
Another limitation is that gastrointestinal symptoms were not evaluated in the control subjects because there were no relevant questions included in the questionnaire. 20 Additionally, performing esophagoscopy with biopsy on control children is not feasible in this birth cohort. It is possible that some children included in the control group could have EoE, but we believe this is unlikely given the prevalence of this disease. 2 Based on a national prevalence estimated to approach 100/100,000 subjects, it is unlikely that there would be more than 1 or 2 cases (if any) in the control cohort.
Measuring antibodies to specific proteins has already provided important information about the IgE response to foods. Using the same approach, we report here that titers of sIgG 4 to CM proteins are greater in children with EoE than in children from an unselected birth cohort. Interestingly, the results also suggest that the relative difference in the magnitude of the sIgG 4 response to CM between children with EoE and control children might be greater in boys than girls. Further investigation into the nature of food sIgG 4 antibodies should inform efforts to unravel the immune response that is causal in patients with EoE, as well as the development of noninvasive biomarkers of disease. E1 Exclusion criteria for the mothers included multiple gestation, gestational age of 22 weeks or greater at recruitment, inability to answer questions in English, and plans to move away from the study area before delivery. There were no exclusion criteria related to disease status for the control subjects (children of the mothers). Of 2128 live singleton births, 1038 children attended an inperson visit in their early teenage years (median age, 12.9 years; interquartile range, 12.5-13.4 years), of whom 773 provided blood and 647 had sufficient serum for the IgE assays. We randomly selected 210 of these 647 samples for assay.
Of the patients with EoE from Nationwide Children's Hospital, 13 children were additionally enrolled in a study evaluating the effectiveness of CM elimination diet over 6 to 8 weeks. E2 Sera were collected before and after the diet as part of the protocol and assayed for sIgG 4 to CM proteins for secondary analyses. For comparison, we measured sIgG 4 titers to CM proteins in sera from 10 children with CM allergy, which was defined as having an sIgE titer to CM of 0.35 IU/mL or greater along with a recent history of anaphylactic reactions within an hour of consuming CM. These sera were collected with informed consent and banked at the University of Virginia.
IgG 4 absorption assays
IgG 4 absorption assays were carried out by coupling 10 mg of nBos d 4 and nBos d 5 (Sigma-Aldrich) to 1 g of cyanogen bromide-activated Sepharose 4B (GE Healthcare, Uppsala, Sweden). The suspension was brought up in PBS to make a 50% suspension. For control experiments, mock beads were created by coupling human serum albumin to Sepharose. An equal volume (approximately 0.5 mL) of serum from 3 patients with EoE (in the present study) and each of the bead suspensions in separate tubes were incubated on a vertical rotator overnight at 48C. Afterward, beads were removed with centrifugation, and sera were assayed for sIgG 4 (Fig E1, A) . These results demonstrated that ImmunoCAP IgG 4 
Solid-phase RIAs for specific IgG using molecular allergens
Solid-phase RIAs were performed to measure specific IgG, specific IgG 1 , and sIgG 4 levels to nBos d 4 and nBos d 5 (Sigma-Aldrich). E3 The allergens were radiolabeled with iodine 125 with chloramine-T. Recombinant Protein G-Sepharose 4B conjugate was obtained from Invitrogen (Camarillo, Calif) for measuring IgG levels. For IgG 4 assays, 10 mg of the anti-human IgG 4 mAb clone RJ4 (Abingdon Health, York, United Kingdom), MH164-4 (Sanquin Blood Supply, Amsterdam, The Netherlands), or HP-6023 (Sigma-Aldrich) was coupled to 1 g of cyanogen bromide-activated Sepharose 4B. For IgG 1 , anti-human IgG 1 mAb clone HP-6001 (Sigma-Aldrich) was used.
We added 0.25 mL of a 50% suspension of the prepared Sepharose media in PBS with 0.3% human serum albumin, 0.5 mL of buffer (0.01 mol/L EDTA, 0.3% human serum albumin, 0.05% NaN 3 , and 0.2% Tween-20 in PBS), and 10 mL of serum to 2-mL polystyrene tubes. The mixture was incubated at room temperature on a vertical rotator for 4 hours. The suspension was centrifuged and washed (in PBS with 0.1% Tween-20) 5 times before 0.5 mL of buffer and 50 mL of radiolabeled allergen (in PBS with 0.3% human serum albumin) were added. The suspension was rotated for 4 hours and washed again. The tubes were measured with a gamma counter, and a standard curve was generated for quantitation. Results were expressed in units per milliliter, with a background of 5 U/mL.
We compared the quantitative accuracy of ImmunoCAP IgG 4 assays and the solid-phase IgG 4 RIA for Bos d 4 and Bos d 5 by using sera from 16 patients with EoE in the current studies (Fig E1, B) . There were close quantitative correlations between the 2 methods for sIgG 4 to Bos d 4 (r S 5 0.97, P < .001) by using the mAb clone HP-6023 and also for sIgG 4 to Bos d 5 by using 3 different mAb clones: HP-6023 (r S 5 0.92, P < .001), MH164-4 (r S 5 0.89, P < .001), and RJ4 (r S 5 0.86, P < .001). By using RIAs, detectable sIgG 4 to Bos d 4 was found in 11 of 16 patients, and detectable sIgG 4 
Total IgG 4 assays
The ImmunoCAP total IgG 4 assay (IgA/IgG Calibrator ImmunoCAP) technique (off-label use) is based on use of anti-k and anti-l light chain mAbs on solid phase to capture antibodies from serum. Bound IgG 4 is then detected with a fluorescence-labeled anti-human IgG 4 mAb. Before running these assays, sera were diluted to 1:50 to 1:100 (or more if necessary) in specific IgA/IgG sample diluent. Of note, the ImmunoCAP instrument does an additional 1:100 dilution, thus the final dilution is 5,000-10,000-fold.
Assay validation experiments demonstrated good dilution linearity (Fig E2,  A) and also a solid-phase binding capacity that is sufficient to handle at least a 128-fold excess of IgG 1 antibodies over IgG 4 antibodies without a decrease in quantitation (Fig E2, B) . Additionally, we measured total IgG 4 levels in sera from 53 subjects in the study using both nephelometry and ImmunoCAP assays and found a very good correlation between the methods (r s 5 0.98 [0.97-0.99], P <.001; Fig E2, C) . The mean percentage coefficient of variation for the ImmunoCAP total IgG 4 assay was 3.4%. The GM (95% CI) was calculated by using positive values (sIgE, > _0.1 IU/mL; sIgG 4 , > _0.07 mg/mL). GM, Geometric mean. 
